Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
Abstract Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation.
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley
2021-09-01
|
| Serija: | Clinical Case Reports |
| Teme: | |
| Online pristup: | https://doi.org/10.1002/ccr3.4782 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|